Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1147 | Endocrine tumours | ECE2015

Expression of shorter isoforms of retinoblastoma interacting zinc-finger protein in seminoma tissues

Rossi Valentina , Rosa Caterina De , Abbondanza Ciro , Zazzo Erika Di , Montcharmont Bruno , Sinisi Antonio Agostino

The full-length retinoblastoma interacting zinc-finger protein (RIZ), codified by ten exons, has tumour suppressive and differentiating properties and is known to be a downstream effector in classical oestrogen target tissue. In many normal and malignant tissues alternative splicing isoforms, RIZ1 and RIZ2, frame-shift mutations and/or exon deletions have been found, but their oncogenic role is still debated. Although the presence of RIZ1 in the testis has been described, in g...

ea0020p185 | Endocrine tumours and neoplasia | ECE2009

Estradiol influences somatostatin receptor expression and potentiates the effects of SOM230 on prostate cells

Rossi Valentina , Bellastella Giuseppe , Visconti Daniela , Abbondanza Ciro , Maione Luigi , Bellastella Antonio , Agostino Sinisi Antonio

Somatostatin (SS) receptors (SSR) expression may be modulated by estrogens in breast cancer cells. Aim of this study was to evaluate the effects of estradiol (E2) on SSR levels in prostate epithelial cells (PEC).Methods: We investigated the effects of E2 and SS-analogue SOM230 combined treatment on two PEC lines: EPN that expresses both ERalfa and beta and CPEC, showing no ERalfa and very low ERbeta expression. Cells starved in red ...

ea0032p524 | Endocrine tumours and neoplasia | ECE2013

The expression of SSTR dominant negative truncated variant sst5tMD4 influences the effects of SOM-230 on prostate cells in vitro

Rossi Valentina , Visconti Daniela , De Rosa Cristina , Abbondanza Ciro , Cioffi Iolanda , De Masi Assunta , Sinisi Antonio Agostino

Introduction: The presence of truncated variant of somatostatin receptors (SSTR) has been demonstrated in pituitary tumours. These variants seems act as dominant negative of SSTR and induce the resistance to SST analogue (SSTA) treatment. A variant of SSTR5, sst5TMD4, has been found to disrupt SST signalling in breast cancer cells. In present study, we assayed the expression of sst5TMD4 in two non-transformed epithelial prostate cell lines (EPC): EPN, derived from a normal sur...